CN102836212B

CN102836212B - Hepatoprotective composition

Info

Publication number: CN102836212B
Application number: CN201210300613.8A
Authority: CN
Inventors: 许震
Original assignee: WUHU NOKAN BIOTECHNOLOGY CO Ltd
Current assignee: WUHU NOKAN BIOTECHNOLOGY CO Ltd
Priority date: 2012-08-22
Filing date: 2012-08-22
Publication date: 2014-10-08
Anticipated expiration: 2032-08-22
Also published as: CN102836212A

Abstract

The invention discloses a hepatoprotective composition, which comprises raw materials and medicinal adjuvants. The raw materials contain the following substances: a radix puerariae extract, reishi shell-broken spore powder, a radix salviae miltiorrhizae extract and a radix astragali extract. Compared with the prior art, the raw materials in the product provided by the invention are the traditional Chinese medicine extracts without side effects, so that the hepatoprotective composition is suitable for long-term use.

Description

One protects the liver compositions

Technical field

The invention belongs to compositions, belong to especially the compositions protecting the liver.

Background technology

Liver is an organ taking metabolic function as master in health, has very complicated physiology, biochemical function.The anatomic tissue feature of liver and contained abundant enzyme thereof, make liver participate in nearly all substance metabolism, and the chemical reaction occurring in liver reaches more than 500 kinds, and people claim that it is human body " chemical plant ".Experimental results demonstrate, animal is being extractd after liver completely, even if give corresponding treatment, at most also can only survive more than 50 hour.

Wine is always the part during people live, and on New Year's Day or other festivals, wine especially can not be absent.But wine is a double-edged sword, a small amount of or responsible drinking is good for health, heavy drinking can impair one's health.

Body is taken in after ethanol in a large number, and a large amount of dehydrogenation oxidations under the catalysis of ethanol dehydrogenase weaken tricarboxylic acid cycle obstacle and fatty acid oxidation and affect lipid metabolism; Also can make alpha-phosphate glycerol increase and promote triglyceride synthetic, cause fat to deposit in hepatocyte, simultaneously ethanol can also excited oxygen molecule, produces the exhaustion that oxygen-derived free radicals causes reductive glutathione in the lipid peroxidation of liver plasma membrane and body, causes alcoholic liver injury.

Excessive potable spirit has become the public health problem of current diet circle growing interest.Survey data shows, in China adult crowd, the ratio of alcoholic is rising, nineteen eighty-two only has 0.21%, and Beijing in 1991 16Ge district survey result accounts for 14.3%, Zhejiang area survey data in 2000 shows that alcoholic accounts for survey group's 14.8%, and alcoholic liver injury incidence rate constantly increases clinically.The routine patients with alcoholic liver disease clinical analysis of No.1 Hospital of Jilin Univ.'s Digestive System Department 237 shows: alcoholic cirrhosis account for liver cirrhosis occur total percentage ratio from 1999 10.8% rise to 2003 24%; The alcoholic liver disease of nearly 20,000 Grown livings in Zhejiang area was investigated in 1999～2000, data shows: crowd's alcoholic liver disease prevalence is 4.34%.In Japan, because hepatic impairment induced by alcohol number accounts for 60%.In western countries, alcoholic liver injury is the main reason that causes liver cirrhosis, because of approximately 44% relevant with alcoholic liver injury in the case of liver cirrhosis death.In the U.S., alcoholic hepatitis occupies 10 in the cause of the death, approximately has every year 1.5 ten thousand people-20,000 people to die from alcoholic hepatitis.Therefore be correctly familiar with the hepatic injury that ethanol causes, diagnose in time and control has great importance.Thereby how to replace the effective preventing alcoholic liver injury of medicine to become the research emphasis of researcher by health product.

Summary of the invention

Technical problem to be solved by this invention is to provide a kind of new compositions that protects the liver.

The technical scheme of technical solution problem of the present invention is: one protects the liver compositions, comprises raw material and pharmaceutic adjuvant, and described raw material contains the material of following weight portion:

The material that preferred compositions contains weight portion:

Described Radix Puerariae extract is prepared by the following method:

Radix Puerariae is pulverized, added water and cellulose mycophenolate, at 25-30 DEG C of reaction 12-24 hour, then be warming up to 90-100 DEG C, reaction 2-5 hour, cool to room temperature, filters, and rotation is concentrated into dry; The weight ratio of Radix Puerariae, water is 1:4-10, and the weight/volume (kg/L) of Radix Puerariae and cellulase is than being 1:0.02-0.1.

Described cellulose mycophenolate is: Trichoderma spp. (trichoderma sp) CGMCC 3.3032.

Described pharmaceutic adjuvant is starch.

Preparation method of the present invention is: the material preparing is poured in granulator, mixed 30 minutes, with volumetric concentration 75% ethanol soft material processed, granulate, 55-60 DEG C of baking 12-14 hour, until moisture 2%-4%, granulate, is distributed into capsule.

Using method of the present invention is every day 2 times, each 3.

Ganoderma spore powder is the light vaporific extremely small spore of picture that in Ganoderma growth phase, the growth and maturity phase ejects from cap, has concentrated the elite of Ganoderma, and its main chemical compositions comprises the chemical compositions such as ganoderan, protein and amino acids.Ganoderan has effect of supplementing QI and nourishing YIN, strengthening the body resistance.

Radix Puerariae is legume pueraria lobata Pueraria lobata.(Willd.) dry root of Ohwi.Its sweet in the mouth is pungent, cool in nature, enters spleen, stomach warp, and its gas is gently clear, yang invigorating expelling pathogenic factors from muscles, and the relieving restlessness of promoting the production of body fluid is quenched the thirst, and the kind wine of controlling amasss, and is medicinal and edible plant, extracts by microbial method, has retained to greatest extent the active ingredient in Radix Puerariae.

Radix Salviae Miltiorrhizae (salvia miltiorrhizan Bge.) is the dry root and rhizome of Labiatae Salvia herbaceos perennial.Its bitter in the mouth, be slightly cold, GUIXIN, Liver Channel.For breast ventral spine pain, dysphoria and insomnia, hepatosplenomegaly.Shennong's Herbal has recorded Radix Salviae Miltiorrhizae, classifies as top gradely, and theory of Chinese medical science thinks that Radix Salviae Miltiorrhizae has promoting blood circulation to restore menstrual flow, effect of the relieving restlessness that clears away heart-fire.Radix Salviae Miltiorrhizae is a kind of Chinese medicine of blood circulation promoting and blood stasis dispelling; can increase capillary network; improve microcirculation; dredging liver inner blood is retarded by silt; by improving the activity of superoxide dismutase in blood, oxygen-derived free radicals in scavenger cell, suppresses content of triglyceride and raises; thereby protection hepatocyte, has assistant protection function to alcoholic hepatic injury.

The Radix Astragali is leguminous plant Radix Astagali Astragalus membranaceus(Fisch.) Bge.var.mongholicus(Bge.) Hsiao or Radix Astragali Astragalus membranaceus(Fisch.) dry root of Bge..Raw using: benefit is defended consolidating superficial resistance, inducing diuresis to remove edema, promoting pus discharge and tissue regeneration strengthening, tonifying Qi and lifting yang; Moxibustion is used: invigorating the spleen and replenishing QI.The Radix Astragali, containing number of chemical composition, comprises astragalus polysaccharides, astragaloside etc.Astragalus polysaccharides is the main bioactive ingredients of the Radix Astragali.Experiment in vivo and vitro and clinical research show in a large number, and astragalus polysaccharides has the several functions such as auxiliary protection, enhancing immunity to chemical liver injury.

In the present invention, Ganoderma spore powder can suppress the lipid peroxidation that causes of free radical that ethanol produces, and suppresses too much free radical and lipid peroxide to hepatocellular destruction, reaches liver-protective effect; Radix Puerariae extract can antagonism superoxide dismutase, and the variation of malonaldehyde, shows as superoxide dismutase activity improving, reduces mda content, reaches liver-protective object; Radix Salviae Miltiorrhizae extract is by improving the activity of superoxide dismutase in blood, oxygen-derived free radicals in scavenger cell, alleviate hepatic cell fattydegeneration due to ethanol and downright bad and suppress content of triglyceride and raise, thereby protection hepatocyte there is significant protective effect to alcoholic hepatic injury; Radix Astragali extract can obviously reduce hepatocyte MDA(malonaldehyde) content, also can make the GSH that reduced raise or recover, there is liver-protective effect.

In the present invention, each raw material is all Chinese medicine extract, has no side effect, should long-term taking.

Detailed description of the invention:

Below in conjunction with embodiment, the present invention is described in detail.

Ganoderma spore powder with cellular wall broken of the present invention is produced by Bozhou Yonggang Pieces Factory Co., Ltd..

Radix Astragali extract, Radix Salviae Miltiorrhizae extract are produced by BAICAO plant Trade Co., Ltd. of Xuancheng City.

The total amount of the TANSHINONES of Radix Salviae Miltiorrhizae extract is 5-10%

The total amount of the astragalus polysaccharides of Radix Astragali extract is 30-70%.

Embodiment 1:

One protects the liver compositions, comprises raw material and pharmaceutic adjuvant, described raw material, the material that adjuvant contains following weight portion:

Radix Astragali extract is produced through following operation:

Radix Puerariae is pulverized, added water and cellulose mycophenolate, 25-30 DEG C of reaction 12 hours, then be warming up to 90-100 DEG C, react 5 hours, cool to room temperature, filters, and rotation is concentrated into dry; The weight ratio of Radix Puerariae, water is 1:4, and the weight/volume (kg/L) of Radix Puerariae and cellulase is than being 1:0.02.

Embodiment 2:

One protects the liver compositions, the material that contains weight portion:

Described Radix Puerariae extract is prepared by the following method:

Radix Puerariae is pulverized, added water and cellulose mycophenolate, 25-30 DEG C of reaction 18 hours, then be warming up to 90-100 DEG C, react 4 hours, cool to room temperature, filters, and rotation is concentrated into dry; The weight ratio of Radix Puerariae, water is 1:8, and the weight/volume (kg/L) of Radix Puerariae and cellulase is than being 1:0.05.

Its production technology is identical with embodiment 1.

Every capsules contains Radix Puerariae extract 52mg, Ganoderma spore powder 156mg, Radix Salviae Miltiorrhizae extract 52mg, Radix Astragali extract 104mg.

Embodiment 3:

Described Radix Puerariae extract is prepared by the following method:

Radix Puerariae is pulverized, added water and cellulose mycophenolate, 25-30 DEG C of reaction 24 hours, then be warming up to 90-100 DEG C, react 2 hours, cool to room temperature, filters, and rotation is concentrated into dry; The weight ratio of Radix Puerariae, water is 1:10, and the weight/volume (kg/L) of Radix Puerariae and cellulase is than being 1:0.1.

Its production technology is identical with embodiment 1.

Embodiment 4:

By capsule made embodiment 2, be made as basic, normal, high three dosage groups, be respectively 0.225g/kg.bw, 0.45g/kg.bw, 1.35g/kg.bw(and be equivalent to respectively 5,10,30 times of human body recommended dose), simultaneously, if blank group and liver injury model matched group, every day, to mouse stomach once continuous 30 days, gavage volume were 0.2ml/10g.bw, and blank group and hepatic injury matched group give distilled water.The 30th day, each dosage group and liver injury model matched group gave 50% ethanol (12ml/10g.bw), cause acute liver damage, and blank group gives equal-volume distilled water, fasting 16 hours, carries out indices detection and histopathologic examination.

Detect malonaldehyde (MDA), reduced glutathion (GSH), triglyceride (TG) in hepatic tissue.

Pathology detect fat and drop in distribution, scope, the area in liver, and mark by following standard:

0 point: hepatocyte lactone drips rareness;

1 point: the hepatocyte of dripping containing fat is no more than 1/4;

2 points: the hepatocyte of dripping containing fat is no more than 1/2;

3 points: the hepatocyte of dripping containing fat is no more than 3/4;

4 points: hepatic tissue is almost dripped replacement by fat.

All positive when malonaldehyde (MDA), reduced glutathion (GSH), triglyceride (TG), or two kinds of indexs and pathology detection is wherein positive, can think that sample has assistant protection function to chemical liver injury.

Embodiment 5:

The impact of body weight: table 1:

	Number of animals	Initial body weight	Mid-term body weight	Latter stage body weight	Weightening finish
						Model contrast	10	19．96g	30.05g	37.03g	17.07g
Blank	10	20.01g	31.22g	37.59g	17.58g
						Low dose group	10	20.08g	30.28g	36.78g	16.7g
Middle dosage group	10	20.06g	30.22g	37.22g	17.16g
						High dose group	10	20.15g	31.20g	37.48g	17.33g

Upper table demonstration, each dosage is given and model control group and the comparison of blank group, and there are no significant for difference (P ﹥ 0.05).

Embodiment 6:

Impact on malonaldehyde in hepatic tissue (MDA), reduced glutathion (GSH), triglyceride (TG):

The unit of malonaldehyde (MDA), reduced glutathion (GSH), triglyceride (TG) is (μ mol/g liver)

Table 2:

	Number of animals	MDA content	P value
				Model contrast	10	0.93
Blank	10	0.54	0.011
				Low dose group	10	0.84	0.887
Middle dosage group	10	0.72	0.294
				High dose group	10	0.65	0.100

Table 3:

	Number of animals	GSH content	P value
				Model contrast	10	5.8
Blank	10	8.57	0.000
				Low dose group	10	6.26	0.853
Middle dosage group	10	6.86	0.233
				High dose group	10	7.54	0.017

Table 4:

	Number of animals	TG content	P value
				Model contrast	10	0.0406
Blank	10	0.0230	0.000
				Low dose group	10	0.0344	0.341
Middle dosage group	10	0.0306	0.051
				High dose group	10	0.0294	0.025

Shown in table 2,3,4, the MDA of model control group, TG all higher than the GSH of blank group, model control group lower than blank group, difference all has significance (P ﹤ 0.05 or P ﹤ 0.01).The TG of high dose group is starkly lower than model control group, and difference all has significance (P ﹤ 0.05).

Embodiment 7:

Pathology effects:

Table 6:

	Number of animals	Change degree	P value
				Model contrast	10	3.4
Blank	10	0.4	0.000
				Low dose group	10	3.2	0.946
Middle dosage group	10	2.8	0.279
				High dose group	10	2.4	0.025

As shown in Table 6, the degree that the liver fat of model control group changes is higher than blank group, and difference all has significance (P ﹤ 0.01).The degree that the liver of high dose group changes is starkly lower than model control group, and difference all has significance (P ﹤ 0.05).

Claims

1. protect the liver a compositions, comprise raw material and pharmaceutic adjuvant, it is characterized in that: described raw material is made up of the material of following weight portion:

Described Radix Puerariae extract is prepared by the following method:

Radix Puerariae is pulverized, added water and cellulose mycophenolate, at 25-30 DEG C of reaction 12-24 hour, then be warming up to 90-100 DEG C, reaction 2-5 hour, cool to room temperature, filters, and rotation is concentrated into dry; The weight ratio of Radix Puerariae, water is 1:4-10, and the weight/volume of Radix Puerariae and cellulase is 1:0.02-0.1.

2. one according to claim 1 protects the liver compositions, it is characterized in that: the material that raw material contains weight portion:

3. one according to claim 2 protects the liver compositions, it is characterized in that: described cellulose mycophenolate is: Trichoderma spp. (trichoderma sp) CGMCC3.3032.